Lenvervimab
Lenvervimab (INN;[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized |
Target | hepatitis B virus surface antigen |
Clinical data | |
Other names | GC1102 |
ATC code |
|
Identifiers | |
CAS Number | |
UNII |
This drug is being developed by GC Pharma. As of 2018, lenvervimab is undergoing Phase II/III trials.
References
- World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.